logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals patients report over 50% pain reduction

These patients are being treated by their doctors under the TGA Special Access Scheme.

xray showing two knees
Patients seeking treatment under the scheme are accelerating

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received positive results from 75 patients with knee osteoarthritis (OA) being treated with its trial drug pentosan polysulfate sodium (PPS).

Of the 75 patients, 84% responded with both a reduction in joint pain and an improvement in knee function.

Notably, patients’ self-reported pain scores were reduced over 50% on average from baseline pain scores.

Superior to 15% pain reduction from opioid treatments

The maintained 50% average reduction in pain scores, observed with PPS in knee osteoarthritis, continues to demonstrate superiority over the opioid treatment alternative.

Historical data previously showed 15% pain reduction scores for opioid treatments for chronic pain in osteoarthritis of the knee and hip.

Real world data support ongoing clinical trials

These patients were treated under a similar dosing regimen as Paradigm’s current phase IIb osteoarthritis clinical trial, which is expected to release results in the coming December quarter.

READ: Paradigm Biopharmaceuticals osteoarthritis clinical trial ahead of schedule

The results from these 75 patients provide important real world evidence data, which can be used in combination with clinical trials to support product registration.

Paradigm will continue to report over the coming months on the groups of patients that are currently undergoing treatment from their doctors under the TGA Special Access Scheme (SAS).

Number of patients seeking treatment accelerating

Paradigm’s CEO Paul Rennie said: “The number of patients seeking treatment via the TGA SAS is accelerating, which we believe is a strong indication that the patients are receiving a clinical benefit from the iPPS treatment.

“Furthermore, it is a significant positive outcome that all these patients have on average, a clinically meaningful reduction in pain of 50%.

“Given these patients have a very similar treatment regimen to subjects being treated under the current phase IIb osteoarthritis randomised, double-blind, placebo-controlled, clinical trial and these patients have failed current therapies to treat OA, we feel particularly confident regarding a positive clinical trial outcome, with the expected release of headline results for that trial due in Q4 CY 2018.”

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.16 AUD

ASX:PAR
Market: ASX
Market Cap: $710.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read